## **REMARKS/ARGUMENTS**

Claims 1-17 remain canceled.

Claims 18-38 remain active.

Applicants respectfully traverse the obviousness rejection of Claims 18-32 and 37-38 as being unpatentable over Ahmad, because Ahmad does not describe or suggest all of the features of, for example, Claim 18 and the claims depending therefrom. Ahmad, at column 2, line 50, describes an ether lipid having the following formula:

$$\begin{array}{c} -\text{O}-\text{Y}_1\text{Y}_2 \\ -\text{Z}-\text{CH}_3 \\ & \oplus \\ \text{O}-\text{P}-\text{O} & \text{Me} \\ \text{O} & \text{O}_{\boxdot} & \text{Me} \end{array}$$

Applicants note that the lipid of <u>Ahmad</u> contains, at a terminal position in the glycerol backbone, a phosphate ester group linked to a trimethyl amino group via an ethylene spacer:

The lipid of Claim 18 is depicted below:

In contrast to <u>Ahmad</u>, the lipid of Claim 18 does not contain, at a terminal position of the glycerol backbone, a phosphate ester group linked to a trimethyl amino group via an ethylene spacer, but rather, at the terminal positions of the glycerol backbone, contains either an ether or an ester (e.g., CH<sub>2</sub>-O-R<sup>1</sup> is an ether linkage [C-O-C], and CH<sub>2</sub>-O-R<sup>3</sup> is an ester

linkage [C-O-C(O)]). Because Ahmad does not describe or suggest the lipid of Claim 18, Applicants respectfully request withdrawal of the obviousness rejection.

The obviousness rejection of Claims 18-32 and 37-38 based on Mayhew is respectfully traversed. Applicants respectfully note that a Certificate of Correction was issued in Mayhew, and that the Markush structure described in the Official Action at page 5 is incorrect. The correct Markush structure, that is constant throughout the specification of Mayhew, is:

Applicants note the ether lipid of <u>Mayhew</u> contains at a terminal position in the glycerol backbone, a phosphate ester group linked to a trimethyl amino group via an ethylene spacer:

In contrast to <u>Mayhew</u>, the lipid of Claim 18 does not contain, at a terminal position of the glycerol backbone, a phosphate ester group linked to a trimethyl amino group via an ethylene spacer, but rather, at the terminal positions of the glycerol backbone, contains either an ether or an ester (e.g., CH<sub>2</sub>-O-R<sup>1</sup> is an ether linkage [C-O-C], and CH<sub>2</sub>-O-R<sup>3</sup> is an ester linkage [C-O-C(O)]). Because <u>Mayhew</u> does not describe or suggest the lipid of Claim 18, Applicants respectfully request withdrawal of the obviousness rejection.

The obviousness rejection of Claims 18-38 in view of <u>Levin</u> and <u>Fuisz</u> is respectfully traversed, because the combined references do not teach or suggest all of the limitations of the present claims.

Application No. 10/517,323 Reply to Office Action of November 20, 2006

<u>Levin</u> is silent regarding reducing formations of skin cancer, pigmented spots, freckles, wrinkles, verrucae, and erythemia induced by ultraviolet light. As these are features of, for example, Claim 18, <u>Levin</u> does not describe or suggest all of the features of Claim 18. <u>Fuisz</u> does not remedy the deficiencies of <u>Levin</u>.

Withdrawal of the rejection is respectfully requested.

Applicants submit the present application is now in condition for allowance. Early notification to this effect is earnestly solicited.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND, MAIER & NEUSTADT, P.C. Norman F. Oblon

 $\begin{array}{c} \text{Customer Number} \\ 22850 \end{array}$ 

Tel: (703) 413-3000 Fax: (703) 413 -2220 (OSMMN 06/04) Charles J. Andres, Ph.D. Registration No. 57,537